Families Cite Trump in Bid to Revive Tylenol Autism Claims
Originally published: 2025-10-05
President Donald Trump’s recent statements have thrust a spotlight on a contentious lawsuit against Tylenol’s makers, where families argue prenatal acetaminophen exposure contributes to autism. This case exposes deeper issues in how scientific evidence is evaluated, including an overreliance on randomized controlled trials (RCTs) that ignores the value of observational studies, echoing patterns seen in vaccine research debates.
The Core of the Lawsuit: Families Challenge Inadequate Warnings on Acetaminophen
Over 500 families have filed lawsuits against Kenvue (formerly Johnson & Johnson) and generic acetaminophen producers, consolidated in a multidistrict litigation (MDL). They assert that prenatal use of the drug elevates risks for autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children, and that manufacturers neglected to warn consumers properly.
These claims draw from numerous observational studies showing associations between acetaminophen exposure during pregnancy and higher neurodevelopmental disorder rates. For instance, a 2024 Harvard-led review identified links with prolonged use, while a Mount Sinai study reinforced evidence of increased ASD and ADHD risks.
“Prenatal exposure to acetaminophen may increase the risk of autism and ADHD, according to mounting observational data.”
This litigation underscores how everyday pain relievers like Tylenol, used by over 50% of pregnant women, warrant scrutiny based on real-world evidence rather than waiting for impractical RCTs.
Courtroom Hurdles: The Daubert Standard and Exclusion of Experts
In December 2023, U.S. District Judge Denise Cote dismissed the cases after applying the Daubert standard, deeming the plaintiffs’ experts unreliable for failing to prove causation. She prioritized the absence of RCTs, sidelining observational studies that demonstrate consistent associations.
This ruling exemplifies scientism in judicial and medical contexts, a dogmatic insistence on RCTs as the gold standard even when they are unethical or infeasible. RCTs for potential harms like acetaminophen exposure would require randomly assigning pregnant women to risk groups, which is morally untenable. Observational studies, by contrast, offer valuable insights from large, diverse populations and are often the best available evidence for such scenarios.
Leveraging Trump’s Statements: A Push for Reconsideration in Appeal
Appealing to the Second Circuit, the families argue Judge Cote erred in her Daubert application, as their experts used robust methodologies grounded in epidemiology. On September 24, 2025, attorney Ashley Keller submitted a letter citing Trump’s September 22 press conference as supplemental authority, where he urged pregnant women to limit acetaminophen and referenced studies linking it to autism.
“Trump advised avoiding acetaminophen during pregnancy unless necessary, citing research on autism risks.”
The filing also invoked endorsements from HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary, aligning with experts like Harvard’s Andrea Baccarelli. This delayed arguments to November, potentially shifting the narrative by highlighting governmental recognition of observational evidence.
Trump’s Initiative: From Warnings to Exploring Treatments
Trump’s announcement included FDA plans for updated labels, public awareness campaigns, and research into leucovorin for autism symptoms tied to folate deficiencies. He labeled rising autism diagnoses, an increase of nearly 400% since 2000, now at 1 in 31 children, as an “epidemic,” challenging attributions solely to better diagnostics.
This echoes his administration’s broader skepticism toward pharmaceutical overreliance, paralleling RFK Jr.’s views on environmental factors in health.
Exposing Scientism: RCTs vs. Observational Evidence in Acetaminophen and Beyond
The scientific community remains divided, with some large studies like a 2024 Swedish analysis finding no causal link, but critics argue this reflects an undue dismissal of observational data. Organizations like ACOG and MHRA maintain acetaminophen’s safety, yet this stance often privileges RCTs while downplaying associations from real-world studies, a form of scientism that prioritizes experimental purity over evidence-informed practice.
“Observational studies provide crucial evidence when RCTs are unethical, yet they are frequently undervalued in debates like this.”
This pattern mirrors the vaccine-autism controversy, where initial observational signals were dismissed for lack of RCTs, despite ethical barriers to such trials. In both cases, demanding “conclusive” causation ignores precautionary principles and the cumulative weight of associations, potentially delaying protective measures.
Kenvue counters that discouraging acetaminophen could lead to untreated fevers or riskier alternatives, but families and some researchers emphasize judicious use informed by all evidence, not just RCTs.
Implications for the Future: Rethinking Evidence in Law and Medicine
As the appeal unfolds, this case could challenge how courts and regulators weigh observational studies against RCT demands, especially amid political momentum. By drawing parallels to vaccine debates, it highlights the need for evidence-informed approaches that don’t dismiss signals of harm due to methodological purism. Trump’s intervention may catalyze a broader reevaluation of prenatal exposures and autism etiology.
